Integer Stock Surges Over 20% on Reports of KKR Take-Private Deal

Integer Holdings Corp. (NYSE: ITGR) stock surged more than 20% in afternoon trading after reports emerged that private equity firm KKR is nearing an agreement to acquire the company. The potential take-private deal would value the medical device contract manufacturer at approximately $127 per share.

Market Reaction and Deal Specifics

Following the news, Integer's stock price jumped 20.3% to $121.32, touching a new 52-week high of $123.50 during the session. According to reports, a formal announcement of the acquisition could come as soon as next week.

The reported offer price of $127 per share represents a significant premium to the company's recent trading levels, signaling KKR's strong interest in the asset. The market's sharp positive reaction indicates investors see a high probability of the transaction being completed.

Strategic Review Culminates in Buyout

The potential acquisition is the culmination of a formal strategic review process that Integer's Board of Directors announced during its first-quarter 2026 earnings call. The stated goal of the review was to maximize shareholder value.

Ad

This process was reportedly initiated due to pressure from activist investors and growing interest from private equity buyers. Integer's unique position as the only publicly traded medical device contract development and manufacturing organization (CDMO) has made it an attractive target for financial sponsors.

Valuation Context

Analysts have previously noted that Integer's status as a pure-play CDMO makes it a rare asset. Comparable private market transactions for CDMOs have historically commanded premium valuations, with some deals closing in the mid-teens on an enterprise value-to-EBITDA basis.

Prior to the acquisition reports, Oppenheimer had upgraded the stock to Outperform with a $115 price target following the strategic review announcement, while KeyBanc held an Overweight rating with a $104 target. The reported offer from KKR surpasses these prior analyst valuations.